A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Pfizer
University of Pennsylvania
Duke University
City of Hope Medical Center
Seagen Inc.
Eli Lilly and Company
Novartis
City of Hope Medical Center
AstraZeneca
Eli Lilly and Company
HUYABIO International, LLC.
HUYABIO International, LLC.
Jonsson Comprehensive Cancer Center
Compugen Ltd
Tempus AI
N.N. Petrov National Medical Research Center of Oncology
Memorial Sloan Kettering Cancer Center
University of Colorado, Denver
NextCure, Inc.
Revolution Medicines, Inc.